Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors

<strong>Objective:</strong> Antipsychotic drug efficacy may have decreased over the decades. We, therefore, present a comprehensive meta-analysis of all placebo-controlled trials in acute schizophrenia, we investigate which trial characteristics have changed over the years and which ones...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí: Leucht, S, Leucht, C, Huhn, M, Chaimani, A, Mavridis, D, Helfer, B, Samara, M, Rabaioli, M, Bächer, S, Cipriani, A, Geddes, J, Salanti, G, Davis, J
Formáid: Journal article
Foilsithe / Cruthaithe: American Psychiatric Publishing 2017
_version_ 1826302985742843904
author Leucht, S
Leucht, C
Huhn, M
Chaimani, A
Mavridis, D
Helfer, B
Samara, M
Rabaioli, M
Bächer, S
Cipriani, A
Geddes, J
Salanti, G
Davis, J
author_facet Leucht, S
Leucht, C
Huhn, M
Chaimani, A
Mavridis, D
Helfer, B
Samara, M
Rabaioli, M
Bächer, S
Cipriani, A
Geddes, J
Salanti, G
Davis, J
author_sort Leucht, S
collection OXFORD
description <strong>Objective:</strong> Antipsychotic drug efficacy may have decreased over the decades. We, therefore, present a comprehensive meta-analysis of all placebo-controlled trials in acute schizophrenia, we investigate which trial characteristics have changed over the years and which ones are moderators of drug-placebo efficacy differences. <strong>Method:</strong> We searched multiple electronic databases, ClinicalTrials.gov and the FDA website. The outcomes were overall efficacy (primary outcome), responder rates, drop-out rates, positive, negative and depressive symptoms, quality of life, functioning, and major side-effects. Multiple potential moderators of overall efficacy were analyzed by meta-regression. <strong>Results:</strong> 167 double-blind randomized controlled trials with 28102 participants were included. The standardized mean difference (SMD) for overall efficacy was 0.47 (95% CrI 0.42,0.51), but accounting for small trial effects/publication bias reduced the SMD to 0.38. 51% in the antipsychotic group versus 30% in placebo had at least a ‘minimal’ response, and 23% versus 14% had a ‘good’ response. Positive symptoms improved more than negative symptoms and depression. There were also small-to medium sized improvements in quality of life and functioning (SMDs 0.35 and 0.34). In the analysis of response predictors, 17 of 26 trial characteristics analyzed changed over the decades. But in a multivariable meta-regression, only industry-sponsorship and increasing placebo response were significant moderators of effect sizes. Importantly, drug response remained stable over time. <strong>Conclusions:</strong> Approximately two times more patients improved under antipsychotics compared to placebo, but only a minority experienced a good response. Industry sponsorship reduced, rather than increased effect sizes. The decrease of effect sizes over the years was caused by increasing placebo response, not by decreasing drug response. Meta-analyses need to take this confounder into account. In drug development, somewhat smaller sample sizes but better selected patients may overcome a possible vicious circle of increasing sample sizes, more variability and smaller effect sizes.
first_indexed 2024-03-07T05:55:45Z
format Journal article
id oxford-uuid:ea6ced45-9327-41b8-96dd-e9de1d8cde04
institution University of Oxford
last_indexed 2024-03-07T05:55:45Z
publishDate 2017
publisher American Psychiatric Publishing
record_format dspace
spelling oxford-uuid:ea6ced45-9327-41b8-96dd-e9de1d8cde042022-03-27T11:02:36ZSixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictorsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ea6ced45-9327-41b8-96dd-e9de1d8cde04Symplectic Elements at OxfordAmerican Psychiatric Publishing2017Leucht, SLeucht, CHuhn, MChaimani, AMavridis, DHelfer, BSamara, MRabaioli, MBächer, SCipriani, AGeddes, JSalanti, GDavis, J<strong>Objective:</strong> Antipsychotic drug efficacy may have decreased over the decades. We, therefore, present a comprehensive meta-analysis of all placebo-controlled trials in acute schizophrenia, we investigate which trial characteristics have changed over the years and which ones are moderators of drug-placebo efficacy differences. <strong>Method:</strong> We searched multiple electronic databases, ClinicalTrials.gov and the FDA website. The outcomes were overall efficacy (primary outcome), responder rates, drop-out rates, positive, negative and depressive symptoms, quality of life, functioning, and major side-effects. Multiple potential moderators of overall efficacy were analyzed by meta-regression. <strong>Results:</strong> 167 double-blind randomized controlled trials with 28102 participants were included. The standardized mean difference (SMD) for overall efficacy was 0.47 (95% CrI 0.42,0.51), but accounting for small trial effects/publication bias reduced the SMD to 0.38. 51% in the antipsychotic group versus 30% in placebo had at least a ‘minimal’ response, and 23% versus 14% had a ‘good’ response. Positive symptoms improved more than negative symptoms and depression. There were also small-to medium sized improvements in quality of life and functioning (SMDs 0.35 and 0.34). In the analysis of response predictors, 17 of 26 trial characteristics analyzed changed over the decades. But in a multivariable meta-regression, only industry-sponsorship and increasing placebo response were significant moderators of effect sizes. Importantly, drug response remained stable over time. <strong>Conclusions:</strong> Approximately two times more patients improved under antipsychotics compared to placebo, but only a minority experienced a good response. Industry sponsorship reduced, rather than increased effect sizes. The decrease of effect sizes over the years was caused by increasing placebo response, not by decreasing drug response. Meta-analyses need to take this confounder into account. In drug development, somewhat smaller sample sizes but better selected patients may overcome a possible vicious circle of increasing sample sizes, more variability and smaller effect sizes.
spellingShingle Leucht, S
Leucht, C
Huhn, M
Chaimani, A
Mavridis, D
Helfer, B
Samara, M
Rabaioli, M
Bächer, S
Cipriani, A
Geddes, J
Salanti, G
Davis, J
Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors
title Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors
title_full Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors
title_fullStr Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors
title_full_unstemmed Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors
title_short Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors
title_sort sixty years of placebo controlled antipsychotic drug trials in acute schizophrenia systematic review bayesian meta analysis and meta regression of efficacy predictors
work_keys_str_mv AT leuchts sixtyyearsofplacebocontrolledantipsychoticdrugtrialsinacuteschizophreniasystematicreviewbayesianmetaanalysisandmetaregressionofefficacypredictors
AT leuchtc sixtyyearsofplacebocontrolledantipsychoticdrugtrialsinacuteschizophreniasystematicreviewbayesianmetaanalysisandmetaregressionofefficacypredictors
AT huhnm sixtyyearsofplacebocontrolledantipsychoticdrugtrialsinacuteschizophreniasystematicreviewbayesianmetaanalysisandmetaregressionofefficacypredictors
AT chaimania sixtyyearsofplacebocontrolledantipsychoticdrugtrialsinacuteschizophreniasystematicreviewbayesianmetaanalysisandmetaregressionofefficacypredictors
AT mavridisd sixtyyearsofplacebocontrolledantipsychoticdrugtrialsinacuteschizophreniasystematicreviewbayesianmetaanalysisandmetaregressionofefficacypredictors
AT helferb sixtyyearsofplacebocontrolledantipsychoticdrugtrialsinacuteschizophreniasystematicreviewbayesianmetaanalysisandmetaregressionofefficacypredictors
AT samaram sixtyyearsofplacebocontrolledantipsychoticdrugtrialsinacuteschizophreniasystematicreviewbayesianmetaanalysisandmetaregressionofefficacypredictors
AT rabaiolim sixtyyearsofplacebocontrolledantipsychoticdrugtrialsinacuteschizophreniasystematicreviewbayesianmetaanalysisandmetaregressionofefficacypredictors
AT bachers sixtyyearsofplacebocontrolledantipsychoticdrugtrialsinacuteschizophreniasystematicreviewbayesianmetaanalysisandmetaregressionofefficacypredictors
AT cipriania sixtyyearsofplacebocontrolledantipsychoticdrugtrialsinacuteschizophreniasystematicreviewbayesianmetaanalysisandmetaregressionofefficacypredictors
AT geddesj sixtyyearsofplacebocontrolledantipsychoticdrugtrialsinacuteschizophreniasystematicreviewbayesianmetaanalysisandmetaregressionofefficacypredictors
AT salantig sixtyyearsofplacebocontrolledantipsychoticdrugtrialsinacuteschizophreniasystematicreviewbayesianmetaanalysisandmetaregressionofefficacypredictors
AT davisj sixtyyearsofplacebocontrolledantipsychoticdrugtrialsinacuteschizophreniasystematicreviewbayesianmetaanalysisandmetaregressionofefficacypredictors